 | |
| Combination of | |
|---|---|
| Indacaterol | Ultra-long-acting beta-adrenoceptor agonist |
| Glycopyrronium bromide | Muscarinic anticholinergic |
| Clinical data | |
| Trade names | Ultibro Breezhaler, Utibron Neohaler, Xoterna Breezhaler |
| Pregnancy category |
|
| Routes of administration | Inhalation only |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| KEGG | |
| CompTox Dashboard (EPA) | |
Indacaterol/glycopyrronium bromide, sold under the brand name Ultibro Breezhaler among others, is a fixed-dose combination medication for inhalation consisting of the following two active ingredients:
- Indacaterol maleate—an ultra-long-acting beta-adrenoceptor agonist (ultra-LABA); [2]
- Glycopyrronium bromide (glycopyrrolate)—a muscarinic anticholinergic.
Indacaterol maleate/glycopyrronium bromide is used as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). [3]
The drug is marketed by Novartis under the trade names Ultibro Breezhaler and Utibron Neohaler in Europe and the United States, respectively. [3] [4] In 2016, Novartis licensed its U.S. commercial rights for Seebri Neohaler and Utibron Neohaler to Sunovion Pharmaceuticals. [5]
